 |
Among the largest 'Vertically Integrated' pharmaceutical companies in India, Aurobindo has robust product portfolio spread over major product areas encompassing CVS, CNS, Anti-Retroviral, Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic with approved manufacturing facilities by USFDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil for both APIs & Formulations and has Global presence with own infrastructure, strategic alliances, subsidiaries & joint ventures. |
 |
Aurobindo’s R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. In the process, Aurobindo develops new drug delivery systems, dosage formulations and applies new technology for better processes. |
 |
|
 |
 |
 |
 |
| 25th - 27th October ’11 :- |
CPhI- World in Frankfurt, Germany at Hall 3 and Stall 30D16 |
|
Important Mile Stones
 |
Merger of APL Life Sciences Ltd & Senor Organics Pvt. Ltd. |
 |
Issue of USD 200 Million FCCBs |
 |
Achieved Turnover of Rs.23 billion |
 |
Establishment of a WOS for Research activities |
| more >> |
|
|
 |
|
|
|
 |
 |
|
|
 |
 |
 |
 |
Stock Prices - December, 11 |
 |
 |
| STOCK EXCHANGE |
OPEN |
HIGH |
LOW |
CLOSE |
VOLUME TRADED |
| BSE |
93.40 |
98.50 |
83.35 |
85.15 |
12,44,664 |
| NSE |
92.80 |
98.30 |
83.05 |
85.15 |
1,92,32,059 |
|
 |
|
|
 |
 |
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
| Aurobindo's R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. |
|
 |
 |
|
|
 |
|
 |
|
|